Searchable abstracts of presentations at key conferences in endocrinology

ea0041ep208 | Cardiovascular Endocrinology and Lipid Metabolism | ECE2016

Optimising human hepatocyte models for metabolic phenotype: effects of treatment with DMSO

Nikolaou Nikolaos , Green Charlotte , Gunn Pippa , Hodson Leanne , Tomlinson Jeremy

Primary human hepatocytes are considered the ‘gold standard’ to explore metabolic phenotype within the liver, however they come with limitations, such as donor variability, lack of proliferation and rapid phenotype loss. The human hepatoma cell line, HepG2, has been used extensively in cell-based metabolic studies but there are significant limitations including their malignant origin and inherent low rates of triglyceride secretion. The aim of this study was to inves...

ea0065oc1.2 | Metabolism and Obesity | SFEBES2019

Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism

Green Charlotte , Pramfalk Camilla , Charlton Catriona , Gunn Pippa , Cornfield Thomas , Pavalides Michael , Karpe Fredrik , Hodson Leanne

Background and Aim: Hepatic de novo lipogenesis (DNL) has been implicated in the development of non-alcoholic fatty liver disease (NAFLD). Supplementation with the omega-3 fatty acids (FA) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) decreases intrahepatic triacylglycerol (IHTAG) and plasma TAG concentrations, which is suggested to be mediated through changes in hepatic DNL. We investigated the effects of omega-3 FA supplementation on intrahepatic DNL an...